Nephrology Dialysis Transplantation, Vol 13, Issue 90002 16-22, Copyright © 1998 by Oxford University Press
E Ritz and K Amann
The optimal target haemoglobin during treatment with recombinant human
erythropoietin (r-HuEPO) is still controversial. The impact of haemoglobin
on cardiovascular function or survival, on physical performance and on
medical rehabilitation have to be taken into consideration. Although
currently there is no solid evidence to show that haemoglobin beyond that
recommended to the ad hoc committee of the National
Kidney Foundation improves survival, sound theoretical arguments can be
offered for this proposition, particularly in cardiac patients. It is
sensible to individualize the target haemoglobin and to avoid rapid
correction of anaemia.Key words: anaemia;
cardiovascular function; haemoglobin; r-HuEPO
ORIGINAL ARTICLES
Optimal haemoglobin during treatment with recombinant human erythropoietin
Department of Internal Medicine, University of Heidelberg, Bergheimer Strasse 56 a, D-69115 Heidelberg, Germany; Corresponding author
![]()
CiteULike
Connotea
Del.icio.us What's this?